Literature DB >> 9234271

Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments.

G Vaidyanathan1, D Affleck, M R Zalutsky.   

Abstract

N-Succinimidyl 3-[211At]astato-2, 4-dimethoxybenzoate (SADMB) was prepared from a trialkylstannyl precursor in about 70-75% yield. With either trimethyl or tri-n-butylstannyl precursor, no temporal effect was found in the astatodestannylation yield. However, the methyl analog gave slightly better yield which was found to be not statistically significant. A monoclonal antibody (MAb) fragment, Mel-14 F(ab')2, could be labeled using SADMB in 28% coupling efficiency. The specific binding of this labeled fragment to tumor homogenates in vitro was 61.0 +/- 0.5% (62.8 +/- 0.9% for the 131I labeled fragment). Paired-label tissue distribution in normal mice showed similar uptake of 131I and 211 At in many tissues. However, by 14.5 h selectivity of spleen, lungs and stomach for Mel-14 F(ab')2 labeled with 211At compared to 131I was 4.1, 3.8 and 6.4, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9234271     DOI: 10.1016/0969-8051(94)90136-8

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  2 in total

1.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

Review 2.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.